Prevalence of PALB2 Mutations in Breast Cancer Patients in Multi-Ethnic Asian Population in Malaysia and Singapore

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Phuah, Sze Yee ^a,b   Lee, Sheau Yee ^a   Kang, Peter ^a   Kang, In Nee ^a   Yoon, Sook Yee ^a   Thong, Meow Keong ^b   Hartman, Mikael ^c   Sng, Jen Hwei ^d   Yip, Cheng Har ^e   Taib, Nur Aishah Mohd ^b   Teo, Soo Hwang ^a,b  

^a CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e Sime Darby Medical Centre   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; ASIAN; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; DNA SEQUENCE; ETHNICITY; FAMILY HISTORY; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MISSENSE MUTATION; PALB2 GENE; PREVALENCE; SINGAPORE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; ETHNIC GROUP; EXON; FAMILY; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PEDIGREE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; ETHNIC GROUPS; EXONS; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALAYSIA; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PEDIGREE; PREVALENCE; SINGAPORE; TUMOR SUPPRESSOR PROTEINS;

EID: 84882575643     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073638     Document Type: Article

References (27)

1. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, et al. (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22: 719-729. doi:10.1016/j.molcel.2006.05.022. PubMed: 16793542.
2. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, et al. (2007) Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162-164. doi:10.1038/ng1947. PubMed: 17200671.
3. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 39: 165-167. doi:10.1038/ng1959. PubMed: 17200668.
4. Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, et al. (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446: 316-319. doi:10.1038/nature05609. PubMed: 17287723.
5. Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, et al. (2007) Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res 9: R83. doi:10.1186/bcr1828. PubMed: 18053174.
6. Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, et al. (2010) A PALB2 mutation associated with high risk of breast cancer. Breast Cancer Res 12: R109. doi:10.1186/bcr2796. PubMed: 21182766.
7. Hollestelle A, Wasielewski M, Martens JW, Schutte M, (2010) Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 20: 268-276. doi:10.1016/j.gde.2010.02.009. PubMed: 20346647.
8. Erkko H, Dowty JG, Nikkilä J, Syrjäkoski K, Mannermaa A, et al. (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin Cancer Res 14: 4667-4671. doi:10.1158/1078-0432.CCR-08-0210. PubMed: 18628482.
9. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, et al. (2011) PALB2 mutations in familial breast and pancreatic cancer. Fam Cancer 10: 225-231. doi:10.1007/s10689-011-9426-1. PubMed: 21365267.
10. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, et al. (2010) PALB2 mutations in European familial pancreatic cancer families. Clin Genet 78: 490-494. doi:10.1111/j.1399-0004.2010.01425.x. PubMed: 20412113.
11. Prokofyeva D, Bogdanova N, Bermisheva M, Zinnatullina G, Hillemanns P, et al. (2012) Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. Clin Genet 82: 100-101. doi:10.1111/j.1399-0004.2011.01824.x. PubMed: 22310028.
12. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, et al. (2010) A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. BMC Med Genet 11: 20. doi:10.1186/1471-2156-11-20. PubMed: 20122277.
13. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, et al. (2009) The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 114: 457-462. doi:10.1007/s10549-008-0036-z. PubMed: 18446436.
14. Zheng Y, Zhang J, Niu Q, Huo D, Olopade OI, (2012) Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer 118: 1362-1370. doi:10.1002/cncr.26388. PubMed: 21932393.
15. Thirthagiri E, Lee SY, Kang P, Lee DS, Toh GT, et al. (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10: R59. doi:10.1186/bcr1943. PubMed: 18627636.
16. Toh GT, Kang P, Lee SS, Lee DS, Lee SY, et al. (2008) BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLOS ONE 3: e2024. doi:10.1371/journal.pone.0002024. PubMed: 18431501.
17. Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, et al. (2007) Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A 104: 6788-6793. doi:10.1073/pnas.0701724104. PubMed: 17420451.
18. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249. doi:10.1038/nmeth0410-248. PubMed: 20354512.
19. Kumar P, Henikoff S, Ng PC, (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081. doi:10.1038/nprot.2009.86. PubMed: 19561590.
20. Ng PC, Henikoff S, (2003) SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 31: 3812-3814. doi:10.1093/nar/gkg509. PubMed: 12824425.
21. Blanco A, de la Hoya M, Balmaña J, Ramón y Cajal T, Teulé A, et al. (2012) Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Res Treat 132: 307-315. doi:10.1007/s10549-011-1842-2. PubMed: 22052327.
22. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, et al. (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39: 159-161. doi:10.1038/ng1942. PubMed: 17200672.
23. Sluiter M, Mew S, van Rensburg EJ, (2009) PALB2 sequence variants in young South African breast cancer patients. Fam Cancer 8: 347-353. doi:10.1007/s10689-009-9241-0. PubMed: 19333784.
24. García MJ, Fernández V, Osorio A, Barroso A, Llort G, et al. (2009) Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat 113: 545-551. doi:10.1007/s10549-008-9945-0. PubMed: 18302019.
25. Ding YC, Steele L, Chu LH, Kelley K, Davis H, et al. (2011) Germline mutations in PALB2 in African-American breast cancer cases. Breast Cancer Res Treat 126: 227-230. doi:10.1007/s10549-010-1271-7. PubMed: 21113654.
26. Haiman CA, Han Y, Feng Y, Xia L, Hsu C, et al. (2013) Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLOS Genet 9: e1003419.
27. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, et al. (2001) Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 10: 353-360. doi:10.1093/hmg/10.4.353. PubMed: 11157798.